Giavonni Lewis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giavonni Lewis has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Camila Vargas
Division of Cardiothoracic Surgery, University of Utah School of Medicine, 3C 127, 30 N 1900 E, Salt Lake City, UT, 84132, USA
1 shared publication - Chloe Skidmore
Division of Cardiothoracic Surgery, University of Utah School of Medicine, 3C 127, 30 N 1900 E, Salt Lake City, UT, 84132, USA
1 shared publication - Craig H. Selzman
Division of Cardiothoracic Surgery, Department of Surgery, University of Utah, Salt Lake City, Utah, USA
1 shared publication - Jan Pierce
Cell Therapy and Regenerative Medicine Program, University of Utah School of Medicine, Salt Lake City, UT, USA
1 shared publication - John D. Phillips
Division of Hematology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT
1 shared publication - Joseph E. Tonna
Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, UT
1 shared publication
Latest Publications
- Open Access
- 22 January 2021
- Published by Springer Nature in BMC Research Notes
- Vol. 14 (1) , 1-5
A pilot trial of human amniotic fluid for the treatment of COVID-19
Objective: Vertical transmission from SARS CoV-2-infected women is uncommon and coronavirus has not been detected in amniotic fluid. Human amniotic products have a broad immune-mediating profile. Observing that many COVID-19 patients have a profound inflammatory response to the virus, we sought to determine the influence of human amniotic fluid (hAF) on hospitalized patients with COVID-19. Results: A 10-patient case series was IRB-approved to study the impact of hAF on hospitalized patients with documented COVID-19. Nine of the 10 patients survived to discharge, with one patient succumbing to the disease when enrolled on maximal ventilatory support and severe hypoxia. The study design was altered by the IRB such that the last 6 patients received higher dose of intravenous hAF. In this latter group, patients that had observed reductions in C-reactive protein were associated with improved clinical outcomes. No hAF-related adverse events were noted. Acknowledging some of the inherent limitations of this case series, these results inform and catalyze a larger scaled randomized prospective trial to further investigate hAF as a therapy for COVID-19. Trial Registration ClinicalTrials.gov: NCT04319731; March 23, 2020
- 22 January 2021
- Published by Springer Nature in BMC Research Notes
- Vol. 14 (1) , 1-5
Open AccessA pilot trial of human amniotic fluid for the treatment of COVID-19
Objective: Vertical transmission from SARS CoV-2-infected women is uncommon and coronavirus has not been detected in amniotic fluid. Human amniotic products have a broad immune-mediating profile. Observing that many COVID-19 patients have a profound inflammatory response to the virus, we sought to determine the influence of human amniotic fluid (hAF) on hospitalized patients with COVID-19. Results: A 10-patient case series was IRB-approved to study the impact of hAF on hospitalized patients with documented COVID-19. Nine of the 10 patients survived to discharge, with one patient succumbing to the disease when enrolled on maximal ventilatory support and severe hypoxia. The study design was altered by the IRB such that the last 6 patients received higher dose of intravenous hAF. In this latter group, patients that had observed reductions in C-reactive protein were associated with improved clinical outcomes. No hAF-related adverse events were noted. Acknowledging some of the inherent limitations of this case series, these results inform and catalyze a larger scaled randomized prospective trial to further investigate hAF as a therapy for COVID-19. Trial Registration ClinicalTrials.gov: NCT04319731; March 23, 2020